Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | L3MBTL3 | Q96JM7 | 2/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | KDM1A | O60341 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25090704 | 0.78 | OPRL1 (0.38) | SMN1; SMN2L3MBTL3L3MBTL1OPRL1HRH3 | |
| SCHEMBL24267573 | 0.74 | OPRL1 (0.35) | SMN1; SMN2L3MBTL3L3MBTL1OPRL1HRH3 | |
| SCHEMBL3168997 | 0.73 | — | — | |
| SCHEMBL26112778 | 0.73 | SMN1; SMN2 (0.52) | CYP2A13SMN1; SMN2L3MBTL3L3MBTL1OPRL1 | |
| SCHEMBL26112782 | 0.73 | SMN1; SMN2 (0.52) | CYP2A13SMN1; SMN2L3MBTL3L3MBTL1OPRL1 | |
| SCHEMBL1150375 | 0.73 | KDM4E (0.48) | CYP2A13SMN1; SMN2EPHX2KDM4EALDH1A1 | |
| SCHEMBL16877830 | 0.72 | — | — | |
| Ammonia Solution, Strong SCHEMBL4295582 | 0.71 | SMN1; SMN2 (0.50) | CYP2A13SMN1; SMN2L3MBTL3L3MBTL1OPRL1 | |
| SCHEMBL14862483 | 0.71 | SMN1; SMN2 (0.50) | CYP2A13SMN1; SMN2L3MBTL3L3MBTL1OPRL1 | |
| SCHEMBL9425142 | 0.69 | SMN1; SMN2 (0.54) | CYP2A13SMN1; SMN2L3MBTL3L3MBTL1OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230065740-A1 | CYCLIN-DEPENDENT KINASE INHIBITORS | SPV THERAPEUTICS INC. | 2023-03-02 | — | — | US | disclosed |
| US-20230048132-A1 | CYCLIN-DEPENDENT KINASE INHIBITORS | SPV THERAPEUTICS INC. | 2023-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230065740-A1 | CYCLIN-DEPENDENT KINASE INHIBITORS | CDK2, CDK1, CCNK | CYP2A13 3226/4885SMN1; SMN2 3671/4885L3MBTL3 3441/4885 |
| US-20230048132-A1 | CYCLIN-DEPENDENT KINASE INHIBITORS | CDK2, CDK1, CCNK | CYP2A13 3226/4885SMN1; SMN2 3671/4885L3MBTL3 3441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.